ICICI Securities has reduce call on with a target price of Rs 985. The current market price of Thyrocare Technologies Ltd. is Rs 1043.25.
Thyrocare Technologies Ltd., incorporated in the year 2000, is a Mid Cap company (having a market cap of Rs 5627.95 Crore) operating in Hospitals & Allied Services sector.
Financials
For the quarter ended 31-03-2021, the company reported a Consolidated Total Income of Rs 150.48 Crore, up 6.84 % from last quarter Total Income of Rs 140.85 Crore and up 45.39 % from last year same quarter Total Income of Rs 103.50 Crore. Company reported net profit after tax of Rs 37.57 Crore in latest quarter.
Investment Rationale
The brokerage raises the revenue and EBITDA estimates for FY22E-FY23E by 4-5% and 1-2% to factor in higher revenue from COVID-19 tests as well as its associated expenses. Considering the recent rally in the stock price we downgrade to REDUCE from Hold with a revised DCF-based target of Rs985/share, implying 30.5xFY23E earnings and 21.7xFY23E EBITDA (earlier: Rs874/share). Key upside risks: faster recovery in preventive care business and incremental tie-ups with standalone labs for sample processing.
Promoter/FII Holdings
Promoters held 66.1 per cent stake in the company as of March 31, 2021, while FIIs held 20.6 per cent, DIIs 7.2 per cent and public and others 6.1 per cent.
